Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.
about
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancerCost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United StatesHuman papillomavirus and HPV vaccines: a reviewAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.The Possible Effects on Socio-Economic Inequalities of Introducing HPV Testing as Primary Test in Cervical Cancer Screening ProgramsA Fuzzy-C-Means-Clustering Approach: Quantifying Chromatin Pattern of Non-Neoplastic Cervical Squamous CellsThe accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials.Genital human papillomavirus infection among women in Bangladesh: findings from a population-based surveyHuman papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis.Intent to participate in future cervical cancer screenings is lower when satisfaction with the decision to be vaccinated is neutral.Immunization in Canada: a 6-year updateAccuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples.HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray system.Canadian oncogenic human papillomavirus cervical infection prevalence: systematic review and meta-analysisClinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.HPV catch-up vaccination of young women: a systematic review and meta-analysis.Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test.Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancerHealth and economic implications of HPV vaccination in the United States.Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination.'A false sense of security'? Understanding the role of the HPV vaccine on future cervical screening behaviour: a qualitative study of UK parents and girls of vaccination age.Immunoprevention of human papillomavirus-associated malignanciesSensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA testComparison of the AdvanSure human papillomavirus screening real-time PCR, the Abbott RealTime High Risk human papillomavirus test, and the Hybrid Capture human papillomavirus DNA test for the detection of human papillomavirus.Breast and gynecological cancers in Croatia, 1988-2008.Commentary: Health inequity could increase in poor countries if universal HPV vaccination is not adopted.New insights into cervical cancer screening.Optimizing technology for cervical cancer screening in high-resource settings.Physicians' intentions to change pap smear frequency following human papillomavirus vaccinationAge-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening."Drivers" of translational cancer epidemiology in the 21st century: needs and opportunitiesHPV and cervical cancer: screening or vaccination?Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UKUsing communication to manage uncertainty about cervical cancer screening guideline adherence among Appalachian women.Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada.HPV immunisation and cervical screening--confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study.Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.Changing trends in the incidence (1999-2011) and mortality (1983-2013) of cervical cancer in the Republic of Korea.Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination.The human papillomavirus vaccine: The promise of cervical cancer prevention
P2860
Q24607403-74F08A11-92AE-4C2A-9368-53F7B9BDF88CQ24655328-A18A6E94-4979-44BA-BCFC-AEE3633AEFC9Q24657891-06BD2571-5D8E-44A8-8684-206EB4E58F28Q26828840-CFA26EEC-0D89-4854-B385-FBB90EEECC51Q26851181-505A89DA-D573-4D18-9653-ECD5FCA4FCEDQ27343102-24AC734A-AEC3-42E3-AC62-C9581B02868FQ30450948-2918005D-4781-4518-AB9C-5EB6B8A83ED4Q30856793-6B4C7062-0809-4F4D-85AC-F3282809BEE5Q30878077-D0FAFBF9-34D9-48D0-86CC-4FEF8A133BA3Q33734307-F5B9DFAB-14B3-44FB-8F88-CC1068396B2EQ33874745-4EA218E4-1121-4FA5-9FCA-8DBEF117EAEDQ33969401-C4ED2D5D-3FC5-43F7-A999-FDAA4CA40F25Q34006684-398A23DD-E327-40C6-ACE7-D1C0FD083873Q34011249-DFF7947F-899B-4FAD-8390-585B864781B1Q34046296-1CC8328B-1CE4-4258-AD60-B4099E1A8D4CQ34157209-BC68D4DD-B839-4DC1-840A-EC35D4076CADQ34250191-A89803F6-9E45-4831-8132-98616C5EEA55Q34596772-93119A06-C429-4F74-8D4D-A94F09512BB9Q34824304-DAC700BC-6C3C-4FA2-9907-40B085AD42EFQ34974475-8921FF07-9455-436A-A4E4-FCF9D060A7CEQ35015922-9C0EFB01-92E1-4B01-B9BB-21EB0F819554Q35044376-1ECDA27D-85CA-4927-9E0F-5DB374A4FFE4Q35140046-C6FC5952-4304-4ACD-AE33-1415D0C92877Q35919848-EEFB7171-CD55-4ABC-BC8D-754694C069D8Q35929355-A7854D4E-A2D2-4D1C-8579-2F9526916FECQ35951206-2BA6F6B1-E522-4BE4-8FCE-912A1D9EAF6BQ36313296-6E8FFA1F-9C01-4475-8152-4B8F99F8F75DQ36319941-5513D425-2F97-409C-97DC-4136D440916BQ36409759-557B1FE8-3F2D-4CB6-88CC-5D54EA5366E0Q36459799-4795EDE3-A1FF-4507-9E0B-6207871C406AQ36589104-C5F8B1D9-E33C-4A4A-B368-ADBECBD46952Q36608826-D325B540-762D-46A4-AB47-CC2A5030CF87Q36610489-89D75288-14D0-4B3D-8CFE-3B3793DD3951Q36639629-CE06991B-1C3D-4872-8832-A8B013232EA7Q36658811-2B459E10-ED4D-4B7C-B478-DC3B04B2A284Q36662008-55BD8830-BE35-4E1E-A6F7-AD2CAA21061DQ36679762-8C480366-8EE6-4A1C-AD02-B4C75F1977FFQ36810164-4B9D023D-2DEF-4EEF-A80E-87605CC3E348Q36839786-8C269405-DFF2-40D2-A1FC-773E13F8527CQ36871265-73058060-5A04-472D-B933-888F1D2AE6C2
P2860
Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.
@ast
Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.
@en
type
label
Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.
@ast
Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.
@en
prefLabel
Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.
@ast
Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.
@en
P50
P1433
P1476
Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.
@en
P2093
Jack Cuzick
P304
P356
10.1016/J.VACCINE.2006.05.061
P407
P478
24 Suppl 3
P577
2006-06-08T00:00:00Z